公开(公告)号：US20230149315A1

公开(公告)日：2023-05-18

申请号：US17784453

申请日：2020-12-11

申请人： Jeffrey SHIMIZU ,  Mitchell Lawrence JONES ,  Mark Sasha DRLIK ,  Iman NIKNIA ,  Nathan John MULLER ,  Tuyen NGUYEN ,  Christopher Loren WAHL ,  Edward MUDGE ,  Nicholas Mark SALT ,  Nia Eleri STEVENS ,  Stuart Robert ABERCROMBIE ,  Christophel Ian BUNCE ,  Ryan Elliott JONES ,  PROGENITY, INC.

发明人： Jeffrey A. SHIMIZU ,  Mitchell Lawrence JONES ,  Mark Sasha DRLIK ,  Iman NIKNIA ,  Nathan John MULLER ,  Tuyen NGUYEN ,  Christopher Loren WAHL ,  Edward MUDGE ,  Nicholas Mark SALT ,  Nia Eleri STEVENS ,  Stuart Robert ABERCROMBIE ,  Christopher Ian BUNCE ,  Ryan Elliott JONES ,  Kevin David HOWE ,  Pejman RAHIMIAN ,  Nelson QUINTANA

IPC分类号： A61K9/48 ,  A61M31/00 ,  A61M37/00

CPC分类号： A61K9/4808 ,  A61M31/002 ,  A61M37/0015 ,  A61M2210/1042 ,  A61M2037/0061

摘要： Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.